The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

De-escalation Misses the Mark in Inflammatory Breast Cancer

2.

10-year study shows tomosynthesis improves breast cancer detection

3.

Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients

4.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

5.

Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot